CBD vs. THC: How Each Cannabinoid Interacts with the Cytochrome P450 Enzyme Pathway

Both cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) are processed in the liver by the Cytochrome P450 (CYP450) enzyme system, which also metabolizes the majority of prescription drugs. This overlap can lead to interactions, thus changing how medications work in the body.

In this post we will go over all the most well known interactions that should be notated when taking any cannabis products along with any prescription or over the counter medications.

While both cannabinoids share some enzyme pathways, they also differ in how strongly they inhibit or compete for metabolism inside the body.

Key Enzymes Involved

Compound	Main CYP450 Enzymes Involved	Effect on Enzymes
CBD	CYP3A4, CYP2C19, CYP2C9, CYP2D6	Strong inhibitor (slows metabolism of many drugs)
THC	CYP2C9, CYP2C19, CYP3A4	Substrate + moderate inhibitor (competes for metabolism, less potent than CBD)

Medication Class Interactions

Here’s a side-by-side look at how CBD vs. THC may interact with major medication groups via CYP450:

Medication Class	CBD Interaction	THC Interaction
Proton-Pump Inhibitors (PPIs)	Inhibits CYP2C19 → ↑ PPI levels, risk of side effects	Competes for CYP2C19/3A4 → moderate ↑ PPI levels
Oral Hypoglycemic Agents	Alters CYP3A4/CYP2C8 metabolism → unstable glucose, ↑ hypoglycemia risk	Similar but milder effect; possible unstable glucose levels
Anesthetics	Inhibits CYP3A4 → prolonged sedation/anesthetic effect	Enhances sedative depth, ↑ respiratory depression risk
Sulfonylureas	Strong inhibition of CYP2C9 → ↑ hypoglycemia risk	Competes with CYP2C9 → ↑ sulfonylurea levels, less pronounced than CBD
Statins (HMG-CoA Reductase Inhibitors)	Inhibits CYP3A4 → ↑ statin levels, muscle/liver toxicity risk	Moderate ↑ in statin levels, similar risks but less potent
Antihistamines	Inhibits CYP2D6/3A4 → ↑ sedation and side effects	Enhances sedation and dry mouth via CYP3A4 competition
Calcium Channel Blockers	Inhibits CYP3A4 → stronger BP-lowering effects, dizziness	Competes with CYP3A4 → ↑ drug effect, possible hypotension
Beta-Blockers	Inhibits CYP2D6 → stronger effects, ↑ bradycardia/hypotension risk	Competes with CYP2D6 → milder but similar risk
Prokinetics	Inhibits CYP3A4 → ↑ drug levels, ↑ movement disorder risk	Competes with CYP3A4 → similar but less potent
Immune Modulators (e.g., Tacrolimus, Cyclosporine)	Strong CYP3A4 inhibition → ↑ toxicity risk	CYP3A4 substrate/competitor → ↑ drug levels, toxicity possible
Benzodiazepines	Inhibits CYP3A4/2C19 → prolonged sedation, cognitive impairment	Competes for same enzymes → ↑ sedation and drowsiness
Antidepressants	Inhibits CYP2D6/3A4/2C19 → ↑ risk serotonin syndrome, stronger side effects	CYP2D6/2C19 competition → mood instability, ↑ side effects
NSAIDs	Inhibits CYP2C9/3A4 → ↑ GI/renal risks	Competes for CYP2C9/3A4 → similar, but less inhibition
Analgesics (Opioids, Codeine, Tramadol)	Inhibits CYP2D6/3A4 → ↑ sedation, respiratory depression risk	Competes for metabolism → amplifies sedation/respiratory risk
Antacids	Do not directly use CYP450; may alter CBD absorption	Same effect; may change THC absorption

Key Differences Between CBD and THC

• CBD is a stronger inhibitor of CYP450 enzymes (especially CYP3A4, CYP2C19, CYP2C9, and CYP2D6). This means CBD more often slows down drug metabolism, leading to higher drug levels.
• THC is both a substrate and moderate inhibitor. It competes for the same enzymes but usually has a less powerful effect on drug levels compared to CBD.
• Both can intensify sedation when combined with CNS depressants (benzodiazepines, anesthetics, opioids).
• CBD tends to have broader interactions because of its stronger enzyme inhibition.
• THC interactions are often more dose-dependent (higher doses = more pronounced interactions).

Practical Takeaways

• If you are on critical medications like statins, immunosuppressants, benzodiazepines, or antidepressants, CBD may present a greater risk of interaction than THC.
• Both compounds can cause dangerous interactions with diabetes drugs, blood pressure medications, and opioids.
• Always consult your healthcare provider before using CBD or THC with prescription medications. Blood work and dose adjustments may be required in order to continue a treatment protocol.

The Bottom Line:
While both CBD and THC interact with the CYP450 system, CBD is a stronger inhibitor, leading to more significant drug interactions. THC tends to compete as a substrate, meaning it still affects drug metabolism but often to a lesser extent. Both require caution, especially because there is a larger increase in elderly people taking multiple medications and also people using cannabis products in addition to medications in order to address their health ailments. Be sure to double check with your physician before using or adding in CBD or THC into your wellness routine.

References:

1. Alsherbiny MA, Li CG. Medicinal Cannabis-Potential Drug Interactions. Medicines (Basel). 2018 Dec 23;6(1):3. doi: 10.3390/medicines6010003. PMID: 30583596; PMCID: PMC6473892.
2. Antoniou T, Bodkin J, Ho JM. Drug interactions with cannabinoids. CMAJ. 2020 Mar 2;192(9):E206. doi: 10.1503/cmaj.191097. PMID: 32122975; PMCID: PMC7055953.
3. Balachandran P, Elsohly M, Hill KP. Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. J Gen Intern Med. 2021 Jul;36(7):2074-2084. doi: 10.1007/s11606-020-06504-8. Epub 2021 Jan 29. PMID: 33515191; PMCID: PMC8298645.
4. Brown JD. Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug-Drug Interactions. J Clin Med. 2020 Mar 27;9(4):919. doi: 10.3390/jcm9040919. PMID: 32230864; PMCID: PMC7231229.
5. Chapin MR, Kane-Gill SL, Li X, Abanyie K, Taneja SB, Egbert S, Paine MF, Boyce RD. Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System. Pharmacol Res Perspect. 2025 Feb;13(1):e70047. doi: 10.1002/prp2.70047. PMID: 39719832; PMCID: PMC11668913.
6. Downs G, Greer R, Moses G, Gurgenci T, Good P, Hardy J. Drug Interactions in People on Cannabidiol: Is There Cause for Concern? Cannabis Cannabinoid Res. 2024 Nov 14. doi: 10.1089/can.2024.0041. Epub ahead of print. PMID: 39539239.
7. Gaston TE, Bebin EM, Cutter GR, Grayson L, Szaflarski JP. Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program. Epilepsia Open. 2023 Dec;8(4):1405-1412. doi: 10.1002/epi4.12815. Epub 2023 Aug 26. PMID: 37593907; PMCID: PMC10690661.
8. Ho JJY, Goh C, Leong CSA, Ng KY, Bakhtiar A. Evaluation of potential drug-drug interactions with medical cannabis. Clin Transl Sci. 2024 May;17(5):e13812. doi: 10.1111/cts.13812. PMID: 38720531; PMCID: PMC11079547.
9. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol Adverse Effects and Toxicity. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. PMID: 31161980; PMCID: PMC7052834.
10. Meissner H, Cascella M. Cannabidiol (CBD) in Clinical Care. [Updated 2024 May 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556048/
11. Nachnani R, Knehans A, Neighbors JD, Kocis PT, Lee T, Tegeler K, Trite T, Raup-Konsavage WM, Vrana KE. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024 May 22;15:1282831. doi: 10.3389/fphar.2024.1282831. PMID: 38868665; PMCID: PMC11167383.
12. Ng T, Gupta V, Keshock MC. Tetrahydrocannabinol (THC) [Updated 2023 Nov 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563174/
13. Qian Y, Gurley BJ, Markowitz JS. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications. J Clin Psychopharmacol. 2019 Sep/Oct;39(5):462-471. doi: 10.1097/JCP.0000000000001089. PMID: 31433338.